# Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

> **NCT03786783** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (actual)

## Conditions studied

- Ganglioneuroblastoma
- High Risk Neuroblastoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexrazoxane
- **BIOLOGICAL:** Dinutuximab
- **DRUG:** Doxorubicin
- **DRUG:** Etoposide
- **RADIATION:** External Beam Radiation Therapy
- **DRUG:** Isotretinoin
- **DRUG:** Melphalan
- **BIOLOGICAL:** Sargramostim
- **DRUG:** Thiotepa
- **DRUG:** Topotecan
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT03786783
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-04
- **Primary completion:** 2021-12-31
- **Final completion:** 2026-09-19
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03786783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03786783, "Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03786783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*